

Unless otherwise defined in this announcement, terms defined in the prospectus of LifeTech Scientific Corporation (the “**Company**”) dated 31 October 2011 (the “**Prospectus**”) have the same meaning when used in this announcement.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus dated 31 October 2011 issued by the Company for detailed information about the Share Offer described below before deciding whether or not to invest in the Offer Shares thereby being offered.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

LISTING ON THE GROWTH ENTERPRISE MARKET OF THE STOCK EXCHANGE OF HONG KONG LIMITED BY WAY OF PLACING AND PUBLIC OFFER

- Number of Offer Shares** : 125,000,000 Shares, comprising
92,500,000 new Shares and 32,500,000
Sale Shares (subject to the
Over-allotment Option)
- Number of Public Offer Shares** : 12,500,000 new Shares (subject to
adjustment)
- Number of Placing Shares** : 112,500,000 Shares, comprising
80,000,000 new Shares and 32,500,000
Sale Shares (subject to adjustment and
the Over-allotment Option)
- Maximum Offer Price** : HK\$2.26 per Offer Share, plus brokerage
fee of 1%, SFC transaction levy of
0.003%, and Hong Kong Stock Exchange
trading fee of 0.005% (payable in full on
application in Hong Kong Dollars and
subject to refund)
- Nominal value** : US\$0.00001 per Share
- Stock code** : 8122

Sponsor, Bookrunner and Lead Manager

Piper Jaffray

Application has been made to the Hong Kong Stock Exchange for the granting of the approval for the listing of, and permission to deal in, (a) the Shares in issue (including the 32,500,000 Sale Shares initially offered to sell by the Selling Shareholders pursuant to the Share offer), (b) 92,500,000 new Shares to be issued pursuant to the Share Offer and (c) Shares to be issued pursuant to the exercise of any options granted under the Share Option Scheme. If the Over-allotment Option is exercised in full, an additional 9,375,000 new Shares will be issued by the Company and an additional 9,375,000 Sale Shares will be sold by the Selling Shareholders, in aggregate representing approximately 15% of the initial Offer Shares available under the Share Offer, namely 125,000,000 Shares.

Applications for the Public Offer Shares will only be considered on the basis of the terms and conditions of the Prospectus and the related Application Forms.

Applicants who wish to be allotted the Public Offer Shares in their own names should (i) complete and sign the **WHITE** Application Forms; or (ii) submit applications online through the designated website of the **HK eIPO White Form** Service Provider at **www.hkeipo.hk** under the **HK eIPO White Form** service.

Applicants who wish to have the Public Offer Shares allotted and issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants should (i) complete and sign the **YELLOW** Application Forms; or (ii) give **electronic application instructions** to HKSCC via CCASS.

Copies of the Prospectus required by the GEM Listing Rules together with the **WHITE** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Monday, 31 October 2011 until 12:00 noon on Thursday, 3 November 2011 from any of the following addresses:

1. Piper Jaffray Asia Securities Limited, Suite 1308, 13/F Two Pacific Place, 88 Queensway, Admiralty, Hong Kong
2. Orient Securities (Hong Kong) Limited, Unit 2404-2407 24/F Man Yee Building, 68 Des Voeux Road Central, Hong Kong
3. China Merchants Securities (HK) Co., Limited, 48/F, One Exchange Square, Central, Hong Kong

4. any of the following branches of Standard Chartered Bank (Hong Kong) Limited:

	Branch Name	Address
Hong Kong	Des Voeux Road Branch	Standard Chartered Bank Building, 4-4A, Des Voeux Road Central, Central
	88 Des Voeux Road Branch	88 Des Voeux Road Central, Central
	Quarry Bay Branch	G/F, Westlands Gardens, 1027 King's Road, Quarry Bay
Kowloon	Kwun Tong Hoi Yuen Road	G/F, Fook Cheong Building, No. 63 Hoi Yuen Road, Kwun Tong, Kowloon
	Mongkok Branch	Shop B, G/F, 1/F & 2/F, 617-623 Nathan Road, Mongkok
	Tsimshatsui Branch	G/F, 10 Granville Road, Tsimshatsui
New Territories	Tsuen Wan Branch	Shop C, G/F & 1/F, Jade Plaza, 298 Sha Tsui Road, Tsuen Wan
	Metroplaza Branch	Shop No. 175 - 176, Level 1, Metroplaza, 223 Hing Fong Road, Kwai Chung

Copies of the Prospectus, together with the **YELLOW** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Monday, 31 October 2011 until 12:00 noon on Thursday, 3 November 2011 from:

- (i) the Depository Counter of HKSCC at 2nd Floor, Infinitus Plaza, 199 Des Voeux Road Central, Hong Kong; or
- (ii) the applicants' broker, who may have such Application Forms and the Prospectus available.

Applicants applying by **HK eIPO White Form** may submit applications to the **HK eIPO White Form** Service Provider through the designated website at **www.hkeipo.hk** from 9:00 a.m. on Monday, 31 October 2011 until 11:30 a.m. on Thursday, 3 November 2011 (or such later time as described under the section headed “How to Apply for the Public Offer Shares — Effect of bad weather on the opening of the application lists” in the Prospectus)(24 hours daily, except on the last application day).

CCASS Participants can input **electronic application instructions** from 9:00 a.m. on Monday, 31 October 2011 until 12:00 noon on Thursday, 3 November 2011.

Acceptance of all applications for the Offer Shares will be conditional on, among other things:

- (i) the Hong Kong Stock Exchange granting the listing of, and permission to deal in, our Shares as described above, and such listing and permission not having been revoked prior to the commencement of dealings in Shares on the Hong Kong Stock Exchange; and
- (ii) the obligations of the Underwriters under each of the respective Underwriting Agreements becoming and remaining unconditional (including, if relevant, as a result of the waiver of any conditions by the Lead Manager, on behalf of the Underwriters) and not having been terminated in accordance with the terms of the respective agreements;

and in each case on or before the dates and times specified in the respective Underwriting Agreements (unless and to the extent such conditions are validly waived on or before such dates and times) and in any event not later than the date which is 30 days after the date of the Prospectus.

Investors should note that the Public Offer Underwriters are, among others, entitled to terminate their obligations under the Public Offer Underwriting Agreement by notice in writing to the Company upon the occurrence of any of the events set forth under “Grounds for Termination” in the section headed “Underwriting” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the date on which the dealings of the Shares commence on GEM Board, which is currently expected to be 10 November 2011.

The Offer Price is expected to be fixed between the Lead Manager, the Company and the Selling Shareholders on the Price Determination Date. The Price Determination Date is expected to be on or before 3 November 2011 or no later than 8 November 2011 in any event. The Offer Price will not be more than HK\$2.26 per Share and is currently expected to be not less than HK\$1.91 per Share unless otherwise announced.

The Lead Manager, with consent of the Company and the Selling Shareholders, may reduce the indicative Offer Price range stated in the Prospectus at any time prior to the morning of Tuesday, 8 November 2011. In such a case, a notice of the reduction of the indicative Offer Price range will be published in the South China Morning Post (in English), the Hong Kong Economic Times (in Chinese), on the Company's website at **www.lifetechmed.com** and the GEM Board website at **www.hkexnews.hk**, not later than the morning of Tuesday, 8 November 2011.

Please refer to the "Structure of the Share Offer" and "How to Apply for the Public Offer Shares" sections of the Prospectus for more details of the conditions and procedures of the Public Offer.

The Company expects to announce the final Offer Price, the level of interest in the Placing, the level of application, results of applications and basis of allocation of the Public Offer Shares under the Public Offer on Wednesday, 9 November 2011, in the South China Morning Post (in English), the Hong Kong Economic Times (in Chinese), on the Company's website at **www.lifetechmed.com** and the website of the Hong Kong Stock Exchange at **www.hkexnews.hk**. Results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Public Offer will be available through a variety of channels from Wednesday, 9 November 2011.

If, for whatever reason, the Lead Manager, the Company and the Selling Shareholders are unable to reach any agreement on the Offer Price on or before the Price Determination Date or such later date as agreed by the Lead Manager, the Company and the Selling Shareholders, the Share Offer will not become unconditional and will lapse. In such event, the Company will issue an announcement in the South China Morning Post (in English), the Hong Kong Economic Times (in Chinese), on the GEM Board website at **www.hkexnews.hk** and the Company's website at **www.lifetechmed.com**.

No receipt will be issued for application monies paid. The Company will not issue temporary documents of title. Share certificates will only become valid documents of title when the Share Offer has become unconditional in all respects and the Underwriting Agreements have not been terminated in accordance with their terms prior to 8:00 a.m. (Hong Kong time) on the Listing Date.

If the Hong Kong Stock Exchange grants the listing of, and permission to deal in, the Shares on GEM Board as mentioned in the Prospectus and the Company complies with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the Listing Date or on any other date HKSCC chooses. Settlement of transactions between participants of the Hong Kong Stock Exchange is required to take place in CCASS on the second business day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made for the Shares to be admitted into CCASS.

Dealings in the Shares on the GEM Board are expected to commence at 9:00 a.m. on Thursday, 10 November 2011. The Shares will be traded in board lots of 2,000 each. The stock code is 8122.

By order of the Board
LifeTech Scientific Corporation
先健科技公司
Liu Jianxiong
Company Secretary

Hong Kong, 31 October 2011

As at the date of this announcement, the executive directors of the Company are XIE Yuehui and ZHAO Yiwei Michael; the non-executive directors of the Company are CONG Ning, LI Gabriel, WU Jianhui and ZENG Min Frank; and the independent non-executive directors of the Company are LIANG Hsien Tse Joseph, ZHANG Xingdong and ZHOU Gengshen.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquires, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement and a copy of the Prospectus will remain on the GEM website at www.hkgem.com and, in the case of the announcement, on the “Latest Company Announcements” page for 7 days from the day of its posting. This announcement and a copy of the Prospectus will also be published on the Company’s website at www.lifetechmed.com.